Global Artemisinin Combination Therapy Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794899
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Artemisinin Combination Therapy Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Rising Demand for Artemisinin Combination Therapy (ACT) is the main factor driving the growth of the market.

Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives in the market are the factors driving the growth of the Artemisinin Combination Therapy market.

Factors, such as limited number of manufacturers globally acts as a hindrance for the market growth.

Pipeline for new antimalarial drugs in the market will create an positive impact in the market in coming years.

Based on type of the market is segmented into artemether+lumefantrine (AL), artesunate+amodiaquine, artesunate+mefloquine (AS+MQ), Dihydroartemisinin+piperaquine (DHA PPQ), artesunate+sulfadoxine-pyrimethamine (AS+SP), and pyronaridine-artesunate (PA)
Artemether+lumefantrine (AL) is the fastest growing segment and it was the first ACT to be launched and prequalified by WHO for its efficacy, safety, and quality.

Based on end-user the market is segmented into hospitals, clinics, pharmacies, research centers and others.

Regionally Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries.

Some of the key players operating in this market include Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals.

Key Benefits of the Report:
* Global, Regional, Country, Type, and Route of End-user Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Type& End-user, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Artemisinin Combination Therapy providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity End-user, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Type Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 ARTEMISININ COMBINATION THERAPY MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Artemisinin Combination Therapy Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Artemisinin Combination Therapy Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Artemisinin Combination Therapy Market Company Market Share, 2017
3.6 Artemisinin Combination Therapy Market — Porter\'s Five Forces Analysis
3.7 Artemisinin Combination Therapy Market — Pestel Analysis

4 ARTEMISININ COMBINATION THERAPY MARKET TYPE OUTLOOK
4.1 Artemisinin Combination Therapy Market Share by Type, 2016 & 2025
4.2 Artemether+Lumefantrine (Al)
4.3 Artesunate+Amodiaquine
4.4 Artesunate+Mefloquine (As+Mq)
4.5 Dihydroartemisinin+Piperaquine (Dha Ppq)
4.6 Artesunate+Sulfadoxine-Pyrimethamine (As+Sp)
4.7 Pyronaridine-Artesunate (Pa)


5 ARTEMISININ COMBINATION THERAPY MARKET END-USER OUTLOOK
5.1 Artemisinin Combination Therapy Market Share by End-user, 2016 & 2025
5.2 Hospitals
5.3 Clinics
5.4Pharmacies
5.5Others

6 ARTEMISININ COMBINATION THERAPY MARKET REGIONAL OUTLOOK
6.1 Artemisinin Combination Therapy Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Artemisinin Combination Therapy Market, 2014 - 2025
6.2.2 North America Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.2.3 North America Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.2.5.2 U.S. Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.2.6.2 Canada Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.3 Europe
6.3.1 Europe Artemisinin Combination Therapy Market, 2014 - 2025
6.3.2 Europe Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.3.3 Europe Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.3.5.2 Germany Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.3.6.2 UK Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Artemisinin Combination Therapy Market, 2014 - 2025
6.4.2 Asia Pacific Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.4.3 Asia Pacific Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.4.5.2 Australia Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Artemisinin Combination Therapy Market, By Type, 2014 -
2025
6.4.6.2 New Zealand Artemisinin Combination Therapy Market, By End-user, 2014 -2025
6.4.7 China
6.4.7.1 China Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.4.7.2 China Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.4.8 India
6.4.8.1 India Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.4.8.2 India Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.4.9.2 Japan Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.5 South America
6.5.1 South America Artemisinin Combination Therapy Market, 2014 - 2025
6.5.2 South America Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.5.3 South America Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.5.5.2 Brazil Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.5.6.2 Mexico Artemisinin Combination Therapy Market, By End-user, 2014 - 2025
6.6 MEA
6.6.1 MEA Artemisinin Combination Therapy Market, 2014 - 2025
6.6.2 MEA Artemisinin Combination Therapy Market, By Type, 2014 - 2025
6.6.3 MEA Artemisinin Combination Therapy Market, By End-user, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Novartis
7.1.2 Financial performance
7.1.3 Type benchmarking
7.1.4 Strategic initiatives
7.2 Sanofi
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Type benchmarking
7.2.4 Strategic initiatives
7.3 Cipla
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Type benchmarking
7.3.4 Strategic initiatives
7.4 Ajanta Pharma
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Type benchmarking
7.4.4 Strategic initiatives
7.5 Ipca Laboratories
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Type benchmarking
7.5.4 Strategic initiatives
7.6 Guilin Pharmaceuticals
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Type benchmarking
7.6.4 Strategic initiatives
7.7 KPC Pharmaceuticals
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Type benchmarking
7.7.4 Strategic initiatives

End of the report
Disclaimer.

Content are not available

Choose License Type